CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Qi, Wenxiu ^a   Xie, Chengzhi ^a,b   Li, Chunhuai ^c   Caldwell, J Timothy ^b   Edwards, Holly ^b   Taub, Jeffrey W ^b,d   Wang, Yue ^c   Lin, Hai ^c   Ge, Yubin ^a,b  

^a JILIN UNIVERSITY   (China)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^d CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Acute myeloid leukemia; Chk1; Mk 1775; Wee1

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; CHECKPOINT KINASE 1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYTARABINE; DOUBLE STRANDED DNA; HISTONE H2AX; LIPOCORTIN 5; PROPIDIUM IODIDE; PROTEIN SERINE THREONINE KINASE; RABUSERTIB; ROSCOVITINE; TYROSINE; UNCLASSIFIED DRUG; WEE1 PROTEIN; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; NUCLEAR PROTEIN; PROTEIN KINASE; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; WEE1 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLAST CELL; CANCER RECURRENCE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CHEMOSENSITIVITY; CHILD; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOCHEMISTRY; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LEUKEMIA CELL LINE; MALE; MIDDLE AGED; MTT ASSAY; PRESCHOOL CHILD; PROTEIN PHOSPHORYLATION; SCHOOL CHILD; TIME; WESTERN BLOTTING; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; CELL CYCLE; DRUG EFFECTS; METABOLISM; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID, ACUTE; NUCLEAR PROTEINS; PROTEIN KINASES; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; TUMOR CELLS, CULTURED;

EID: 84929279071     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-014-0053-9     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X, Meshinchi S, Degar B, Airewele G, Raimondi SC, Onciu M, Coustan-Smith E, Downing JR, Leung W, Pui CH, Campana D: Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial. The lancet oncology 2010, 11:543-552.
3. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA: DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008, 8:193-204.
4. Parker LL, Piwnica-Worms H: Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992, 257:1955-1957.
5. Watanabe N, Broome M, Hunter T: Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. EMBO J 1995, 14:1878-1891.
6. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H: Mitotic and G2 checkpoint control: Regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997, 277:1501-1505.
7. Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, Elledge SJ: Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 1997, 277:1497-1501.
8. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, Donehower LA, Elledge SJ: Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000, 14:1448-1459.
9. Zhao H, Piwnica-Worms H: ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 2001, 21:4129-4139.
10. Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, Kimura T, Kaneko N, Ohtani J, Yamanaka K, Itadani H, Takahashi-Suzuki I, Fukasawa K, Oki H, Nambu T, Jiang J, Sakai T, Arakawa H, Sakamoto T, Sagara T, Yoshizumi T, Mizuarai S, Kotani H: Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009, 8:2992-3000.
11. Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD, Toniatti C, Ashworth A, Turner NC: Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov 2012, 2:524-539.
12. Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, Molkentine JM, Mason KA, Meyn RE: MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res 2011, 17:5638-5648.
13. Chaudhuri L, Vincelette ND, Koh BD, Naylor RM, Flatten KS, Peterson KL, McNally A, Gojo I, Karp JE, Mesa RA, Sproat LO, Bogenberger JM, Kaufmann SH, Tibes R: CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo. Haematologica 2014, 99:688-696.
14. Guertin AD, Li J, Liu Y, Hurd MS, Schuller AG, Long B, Hirsch HA, Feldman I, Benita Y, Toniatti C, Zawel L, Fawell SE, Gilliland DG, Shumway SD: Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-Agent anticancer therapy. Mol Cancer Ther 2013, 12:1442-1452.
15. Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, Imagaki K, Ohtani J, Sakai T, Yoshizumi T, Mizuarai S, Iwasawa Y, Kotani H: MK-1775, a small molecule Wee1 inhibitor, enhances anti-Tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010, 9:514-522.
16. Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H, Gattermann N: The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-Trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006, 106:112-119.
17. Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, Shumway SD, Mizuarai S, Hirai H, Maitra A, Hidalgo M: MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 2011, 17:2799-2806.
18. Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, Reigan P, Porter CC: Inhibition of Wee1 Sensitizes Cancer Cells to Antimetabolite Chemotherapeutics In Vitro and In Vivo, Independent of p53 Functionality. Mol Cancer Ther 2013, 12:2675-2684.
19. Krajewska M, Heijink AM, Bisselink YJ, Seinstra RI, Sillje HH, de Vries EG, van Vugt MA: Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. Oncogene 2013, 32:3001-3008.
20. Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, Kinders RJ, Parchment RE, Doroshow JH, Pommier Y: Histone gammaH2AX and poly (ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res 2010, 16:4532-4542.
21. Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I, Pelicci PG: The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993, 74:423-431.
22. Lin RJ, Sternsdorf T, Tini M, Evans RM: Transcriptional regulation in acute promyelocytic leukemia. Oncogene 2001, 20:7204-7215.
23. Hoemme C, Peerzada A, Behre G, Wang Y, McClelland M, Nieselt K, Zschunke M, Disselhoff C, Agrawal S, Isken F, Tidow N, Berdel WE, Serve H, Muller-Tidow C: Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip. Blood 2008, 111:2887-2895.
24. Russell MR, Levin K, Rader J, Belcastro L, Li Y, Martinez D, Pawel B, Shumway SD, Maris JM, Cole KA: Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. Cancer Res 2013, 73:776-784.
25. Carrassa L, Chila R, Lupi M, Ricci F, Celenza C, Mazzoletti M, Broggini M, Damia G: Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle 2012, 11:2507-2517.
26. Davies KD, Cable PL, Garrus JE, Sullivan FX, von Carlowitz I, Huerou YL, Wallace E, Woessner RD, Gross S: Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation. Cancer Biol Ther 2011, 12:788-796.
27. Taub JW, Matherly LH, Stout ML, Buck SA, Gurney JG, Ravindranath Y: Enhanced metabolism of 1-beta-D-Arabinofuranosylcytosine in Down syndrome cells: A contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood 1996, 87:3395-3403.
28. Niu X, Wang G, Wang Y, Caldwell JT, Edwards H, Xie C, Taub JW, Li C, Lin H, Ge Y: Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. Leukemia 2014, 28:1557-1560.
29. Xie C, Edwards H, Xu X, Zhou H, Buck SA, Stout ML, Yu Q, Rubnitz JE, Matherly LH, Taub JW, Ge Y: Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res 2010, 16:5499-5510.
30. Xu X, Xie C, Edwards H, Zhou H, Buck SA, Ge Y: Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells. Plos One 2011, 6:e17138.
31. Ge Y, Dombkowski AA, LaFiura KM, Tatman D, Yedidi RS, Stout ML, Buck SA, Massey G, Becton DL, Weinstein HJ, Ravindranath Y, Matherly LH, Taub JW: Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood 2006, 107:1570-1581.
32. Ge Y, Stout ML, Tatman DA, Jensen TL, Buck S, Thomas RL, Ravindranath Y, Matherly LH, Taub JW: GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J Natl Cancer Inst 2005, 97:226-231.
33. Edwards H, Xie C, LaFiura KM, Dombkowski AA, Buck SA, Boerner JL, Taub JW, Matherly LH, Ge Y: RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: Role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood 2009, 114:2744-2752.
34. Wang G, He J, Zhao J, Yun W, Xie C, Taub JW, Azmi A, Mohammad RM, Dong Y, Kong W, Guo Y, Ge Y: Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. Plos One 2012, 7:e52095.